CLINICAL FEATURES OF PARKINSON'S DISEASE AND SECONDARY PARKINSONISM (literary review)
Keywords:
Parkinson's disease, secondary parkinsonism, vascular parkinsonism, atypical parkinsonism, clinical manifestations, differential diagnosis, pathogenesis, neurodegenerative diseasesAbstract
Parkinson’s disease (PD) is a widespread neurodegenerative disorder characterized by progressive development and the presence of both motor and non-motor symptoms. Secondary parkinsonism is a complication of another disease with a known etiology (such as cerebrovascular damage, trauma, tumors, hydrocephalus, medication therapy, or toxic exposure). Understanding the clinical differentiation of these pathological conditions plays a key role in making an accurate diagnosis and selecting the optimal treatment strategy. The purpose of this review article is to systematize current knowledge about the pathogenesis and clinical manifestations of Parkinson’s disease, as well as to analyze other conditions presenting with parkinsonism syndrome, including vascular, drug-induced, and atypical parkinsonism.
References
Гашилова Ф.Ф. Клинические и параклинические аспекты паркинсонизма в Томске. Автореферат дис... канд. мед. наук. Новосибирск, 2016.
заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.
Левин О.С. Сосудистый паркинсонизм: 20 лет спустя. РМЖ 2020; №21: с.1500-1506.
Левин О.С. Экстрапирамидные синдромы при цереброваскулярных заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.
Baldereschi M., Di Carlo A., Vanni P., et al. Italian Longitudinal Study on Aging Working Group. Lifestyle-related risk factors for Parkinson's disease: a population-based study. Ada Neurol Scand 2003; №108: 10: 239-244.
Benito–León J., Bermejo-Pareja F., Morales-Gonzalez J.M. et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004; 734-741.
Blauwendraat C., Nalls M.A., Singleton A. B. The genetic architecture of Parkinson's disease. Lancet Neurology 2020; №19(2):170-178.
Coon E.A., Singer W. Synucleinopathies. Continuum 2020; №26(1):72-92.
Factor S. A., Weiner W.J. Parkinson's Disease. Diagnosis and Clinical Management. 2008; 819.
Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol .Neurosurg. Psychiatry 2022; № 51 (6): 745-752.
Hirtz D., Thurman D.J., Gwinn-Hardy K., et al. How common are the "common" neurologic disorders? Neurology 2017; № 68: 326-337.
Höllerhage M. Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. Neurobiol 2019; №149:377-418.
Jellinger K.A. Vascular parkinsonism. Therapy 2008; № 5(2): 237–255.
Kovacs G.G. Tauopathies. Clin Neurol 2017; №145: 355-368.
Lang A.E. Corticobasal degeneration: selected developments. Mov Disord 2013; №18 (6): 51-56.
McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; №89: c. 1–13.
Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2015; №83 (4): 430–436.
Schapira A. H., Jenner J. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2018; №26(6):1049-55.
Terashi H., Taguchi T., Aizawa H. Secondary parkinsonism. Nihon Rinsho 2017; №75 (1): 63-70.
Twelves D., Perkins K.S., Counsell С. Systematic review of incidence studies of Parkinson's disease. MovDisord 2003; №18 (1): 19-31.
Van Den Eeden S.K., Tanner C.M., Bernstein A.L. et al. lncidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; №157: 1015-1022.
Wirdefeldt K., Adami H.O., Cole P., et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; №26(1): 1-58.
